Global Histone Deacetylase Inhibitors Market Set for Strong Expansion, Reaching $1.81 Billion With 6.8% CAGR by 2030
Uncover key drivers, emerging technologies, and competitive movements shaping the histone deacetylase inhibitors market from 2026–2035 with trusted insights from The Business Research Company
What is the estimated market size of the Histone Deacetylase Inhibitors Market by the end of 2030?
The histone deacetylase inhibitors market has experienced robust expansion over recent years. Its size is projected to increase from $1.29 billion in 2025 to $1.39 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.6%. This historical growth can be attributed to factors such as the initial success of hdac inhibitors in treating hematological malignancies, an increasing comprehension of epigenetic regulation in disease, the availability of approved first-generation hdac inhibitors, the broadening of cancer research infrastructure, and heightened investment in targeted cancer therapies.
The histone deacetylase inhibitors market is projected to experience substantial expansion in the coming years, anticipated to reach $1.81 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.8%. Factors contributing to this expansion during the forecast period include the increasing global occurrence of cancer, an expanding array of epigenetic-based treatments under development, a heightened emphasis on individualized oncology strategies, the broadening scope of clinical trials for conditions related to neurology and inflammation, and the need for more targeted and secure epigenetic medications. Key developments expected during this timeframe involve the greater integration of hdac inhibitors into cancer treatment plans, an intensifying focus on selective and isoform-specific hdac inhibitors, a growing uptake of treatment regimens combining hdac inhibitors with other drugs, the extension of hdac inhibitor research into non-cancer areas, and consistent progress in the development of oral hdac inhibitor formulations.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17170&type=smp
What Drivers Are Shaping Future Opportunities In The Histone Deacetylase Inhibitors Market?
A projected rise in cancer cases is anticipated to drive expansion within the histone deacetylase inhibitors market moving ahead. This upward trend in cancer occurrence largely stems from demographic shifts towards older populations, greater contact with risk factors like tobacco use, dietary habits, and environmental contaminants, alongside enhanced diagnostic methods enabling quicker and more regular identification. Histone deacetylase inhibitors combat cancer through modifying chromatin architecture, which results in turning on tumor suppressor genes and turning off oncogenes, consequently causing cell cycle halt and programmed cell death in malignant cells. As an illustration, data from February 2024 by the World Health Organization, a US-based intergovernmental organization, indicated that around 35 million fresh cancer diagnoses are forecasted for 2050, representing a 77% surge from the approximately 20 million cases recorded in 2022. Consequently, the growing number of cancer diagnoses is fueling the expansion of the histone deacetylase inhibitors market.
Which Segments Are Gaining Traction In The Histone Deacetylase Inhibitors Market?
The histone deacetylase inhibitors market covered in this report is segmented –
1) By Classification: Class I Histone Deacetylases (HDACs), Class II Histone Deacetylases (HDACs), Class III Histone Deacetylases (HDACs), Other Classifications
2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Oncology, Neurology, Other Applications
5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Class I Histone Deacetylases (HDACs): HDAC1 Inhibitors, HDAC2 Inhibitors, HDAC3 Inhibitors, HDAC8 Inhibitors
2) By Class II Histone Deacetylases (HDACs): HDAC4 Inhibitors, HDAC5 Inhibitors, HDAC6 Inhibitors, HDAC7 Inhibitors, HDAC9 Inhibitors, HDAC10 Inhibitors
3) By Class III Histone Deacetylases (HDACs): Sirtuin 1 (SIRT1) Inhibitors, Sirtuin 2 (SIRT2) Inhibitors, Sirtuin 3 (SIRT3) Inhibitors, Sirtuin 4 (SIRT4) Inhibitors, Sirtuin 5 (SIRT5) Inhibitors, Sirtuin 6 (SIRT6) Inhibitors, Sirtuin 7 (SIRT7) Inhibitors
4) By Other Classifications: Dual-acting HDAC Inhibitors, Pan-HDAC Inhibitors, Selective HDAC Inhibitors, Combination Inhibitors (HDAC + Other Mechanisms)
Which Market Trends Are Opening Growth Opportunities In The Histone Deacetylase Inhibitors Market?
Leading companies in the histone deacetylase inhibitors market are concentrating on developing innovative product forms, such as oral histone deacetylase (HDAC) inhibitors, to expand available treatment options and improve patient convenience and adherence. An oral histone deacetylase (HDAC) inhibitor is a medication administered by mouth that targets HDAC enzymes involved in gene regulation and is potentially utilized in treating various conditions, including cancer and inflammatory diseases. For example, in March 2024, Italfarmaco S.p.A., an Italy-based pharmaceutical company, obtained Food and Drug Administration approval for Duvyzat (givinostat), an oral histone deacetylase (HDAC) inhibitor, for the management of Duchenne muscular dystrophy (DMD) in patients aged 6 years and older. Duvyzat functions as a histone deacetylase (HDAC) inhibitor that alleviates the sequence of events leading to muscle damage, potentially slowing the progression of muscle deterioration associated with DMD. By inhibiting HDAC overactivity, it diminishes inflammation and fibrosis while promoting muscle fiber regeneration. The approval is based on the pivotal phase 3 EPIDYS trial, which met its primary endpoint, demonstrating that patients treated with Duvyzat exhibited a statistically significant reduction in the time needed to complete the four-stair climb assessment compared to a placebo.
Who Are The Core Companies Influencing Trends In The Histone Deacetylase Inhibitors Market?
Major companies operating in the histone deacetylase inhibitors market are Syndax Pharmaceuticals Inc., MEI Pharma Inc., Italfarmaco S.p.A., Shenzhen Chipscreen Biosciences Co. Ltd., Celgene Corporation, Spectrum Pharmaceuticals Inc., Curis Inc., Onxeo SA, Celleron Therapeutics, Forum Pharmaceuticals Inc., Merck & Co. Inc., AstraZeneca plc, Novartis AG, Eisai Co. Ltd., Karyopharm Therapeutics Inc., Medivir AB, Huya Bioscience International LLC, Crystal Genomics Inc., Midatech Pharma PLC, Regenacy Pharmaceuticals Inc.
Access The Complete Report For Deeper Market Insights:
Which Regions Are Projected To Dominate The Histone Deacetylase Inhibitors Market In The Coming Years?
North America was the largest region in the histone deacetylase inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Histone Deacetylase Inhibitors Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=17170&type=smp
Browse Through More Reports Similar to the Global Histone Deacetylase Inhibitors Market 2026, By The Business Research Company
Histone Deacetylase Inhibitors Market Report 2026
Histone Deacetylase Inhibitors Market Report 2026
Enzyme Inhibitor Market Report 2026
https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
